TUDCA

Tauroursodeoxycholic acid (TUDCA) is the taurine conjugate of ursodeoxycholic acid (UDCA), a hydrophilic bile acid prescribed clinically for primary biliary cholangitis, primary sclerosing cholangitis, and other cholestatic liver diseases. The conjugation with taurine improves intestinal absorption and shifts the molecule’s interaction with hepatic bile-acid receptors compared to free UDCA.

Mechanism — bile acid pool displacement:

Normal hepatic bile contains a mix of hydrophilic (cholic, ursodeoxycholic) and hydrophobic (chenodeoxycholic, lithocholic) bile acids. Hydrophobic bile acids are membrane-toxic to hepatocytes at concentrations that build up in cholestatic injury — the alkylated-oral AAS pattern. TUDCA administration shifts the pool composition toward hydrophilic species through competitive substitution at the bile-acid synthesis and transport pathways.

Independently of bile-acid pool effects, TUDCA acts directly on the unfolded-protein response (UPR) in the endoplasmic reticulum, reducing ER stress in hepatocytes. This mechanism is documented in multiple cell-culture and animal models and is part of the rationale for TUDCA use in non-cholestatic hepatic stress contexts including AAS exposure.

Clinical evidence base:

– Primary biliary cholangitis: solid Cochrane-level evidence for UDCA improving liver biochemistry and slowing disease progression. TUDCA shows comparable efficacy with marginally better tolerability.
– AAS-specific data: anecdotal but mechanistically aligned with the cholestatic injury pattern documented in Nasr & Ahmad 2009, Dig Dis Sci case report on Superdrol-induced cholestasis.
– Mechanistic plausibility for hepatoprotection during 17α-alkylated oral exposure is high; controlled trials specific to AAS users are absent.

Dosing protocol:

– Standard hepatoprotection during oral AAS: 500 mg/day, split 250 mg AM and 250 mg with evening meal
– Harsh compound exposure (oxymetholone, methyltestosterone, fluoxymesterone): 750–1000 mg/day
– Pre-loading: start 7 days before first oral dose to achieve steady-state cytoprotection before exposure begins
– Continue 2 weeks past last oral dose to cover residual exposure as alkylated metabolites clear

Tolerability:

TUDCA is generally well-tolerated. Reported side effects: occasional GI upset (resolved with food), rare diarrhoea at higher doses. No documented hepatic, renal, or endocrine adverse effects at hepatoprotective doses.

What TUDCA does not do:

TUDCA reduces the magnitude of ALT/AST elevation during oral AAS exposure — it does not eliminate elevation. Expected ALT change at week 4 of moderate oral cycle (methandrostenolone 30 mg/day): with TUDCA 50–100% above baseline; without TUDCA 150–300% above baseline. The number still goes up; the supplement is doing work even when bloodwork shows elevation.

TUDCA is insurance against expected hepatic stress, not permission for extended high-dose oral exposure. Pharmacological discipline — 6–8 week oral cycle ceiling, dose-range respect, bloodwork monitoring — is the protective factor that cannot be replaced by supplementation.